Bruin Biometrics Awarded $1.4M NIH Grant Toward Development of Orthopedic Diagnostic


LOS ANGELES and MANCHESTER, England, /PRNewswire/ -- BBI ("Bruin Biometrics, LLC"), a technology company committed to modernizing health care with biometric sensor technology for the early detection and monitoring of chronic, preventable conditions in collaboration with clinicians, today announced receipt of a $1.4 million Small Business Innovation Research (SBIR) Phase II program award from The National Institute of Arthritis and Musculoskeletal and Skin division of the National Institutes of Health.

This award will aide BBI in supporting detection capabilities, design and clinical evaluation of the OrthoSonos, a novel device intended to advance the standard of care in orthopedics with acoustic emission technology. The device is under development to detect joint failure by assessing the friction across the full range of motion. Since x-ray only provides a static image of the joint and the OrthoSonos is based on data gathered from the full dynamic range, the information provided by the device can augment the standard of care with an eye toward earlier detection. Earlier detection can dramatically reduce the complications commonly associated with revision surgeries.

"While complication rates are low, the high volume of knee replacement surgeries and our increasingly aging population stress the importance of increased joint monitoring and prevention," said Martin Burns, Chief Executive Officer. "We are developing OrthoSonos as a health monitor for natural and artificial joints to support clinicians in their prevention efforts. Receiving a Phase II SBIR award demonstrates the incredible impact a prevention tool will have on this space."

BBI previously demonstrated the feasibility of this technology during an earlier funding period, which included a $150k SBIR NIH Phase I program award.

About BBI

Bruin Biometrics, LLC, or BBI, is a pioneer in modernizing health care with biometric sensor technology for early detection and monitoring of chronic, preventable conditions in collaboration with clinicians.

BBI's first product to market is the SEM Scanner, which is a hand-held, portable, skin tissue assessment device that measures sub-epidermal moisture (also known as localised oedema) which is an invisible precursor to the development of incipient pressure damage.

BBI is also developing P02M, the first device for monitoring tissue oxygenation at a specific location in real time. P02M is initially being tested for continual monitoring of tissue and vascular viability in the feet of diabetics. Diabetes can cause peripheral artery disease and peripheral neuropathy, putting patients at risk for foot ulcers.

BBI is based in Los Angeles and maintains a European office in Manchester, UK.

For additional information, visit Follow BBI on Twitter at

BBI Company Contact:
Martin Burns
Chief Executive Officer
+1 (310) 268-9494

Media Contact:
Brittanie Dougherty
Russo Partners
+1 (646) 942-5634



Cision View original content:



Back to news